248 related articles for article (PubMed ID: 14508154)
21. Two new treatment options for infections due to drug-resistant gram-positive cocci.
Rehm SJ
Cleve Clin J Med; 2002 May; 69(5):397-401, 405-13. PubMed ID: 12022383
[TBL] [Abstract][Full Text] [Related]
22. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.
Vinken A; Li Z; Balan D; Rittenhouse B; Wilike R; Nathwani D
J Hosp Infect; 2001 Dec; 49 Suppl A():S13-24. PubMed ID: 11926436
[TBL] [Abstract][Full Text] [Related]
24. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
25. Experience with linezolid therapy in children with osteoarticular infections.
Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
[TBL] [Abstract][Full Text] [Related]
26. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
Gonzales RD; Schreckenberger PC; Graham MB; Kelkar S; DenBesten K; Quinn JP
Lancet; 2001 Apr; 357(9263):1179. PubMed ID: 11323048
[TBL] [Abstract][Full Text] [Related]
27. Linezolid: a review of its use in the management of serious gram-positive infections.
Perry CM; Jarvis B
Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
[TBL] [Abstract][Full Text] [Related]
28. Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin.
Zervos M
New Horiz; 1996 Aug; 4(3):385-92. PubMed ID: 8856757
[TBL] [Abstract][Full Text] [Related]
29. Linezolid for the treatment of resistant gram-positive cocci.
Bain KT; Wittbrodt ET
Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
31. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of linezolid in liver transplant patients.
Radunz S; Juntermanns B; Kaiser GM; Treckmann J; Mathe Z; Paul A; Saner FH
Transpl Infect Dis; 2011 Aug; 13(4):353-8. PubMed ID: 21355969
[TBL] [Abstract][Full Text] [Related]
33. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
34. [Linezolid-resistant Enterococcus faecium: the first G2576T mutation in Turkey].
Afşar I; Barış I; Sener AG; Köksal V; Demirci M
Mikrobiyol Bul; 2012 Jul; 46(3):516-8. PubMed ID: 22951666
[TBL] [Abstract][Full Text] [Related]
35. Current and new antimicrobial agents.
Eliopoulos GM
Am Heart J; 2004 Apr; 147(4):587-92. PubMed ID: 15077072
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis.
Broder KW; Moise PA; Schultz RO; Forrest A; Schentag JJ
Ann Plast Surg; 2004 Apr; 52(4):385-90. PubMed ID: 15084884
[TBL] [Abstract][Full Text] [Related]
38. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
[TBL] [Abstract][Full Text] [Related]
39. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
40. [Enterococcus faecium cholangitis resistant to vancomycin and quinupristin-dalfopristin].
Maseda E; Uña R; Ureta P; Royo C
Med Clin (Barc); 2002 Sep; 119(7):276-7. PubMed ID: 12236991
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
